PvGTSeq and PvCRiSP: Plasmodium Vivax Genomic Surveillance Data by Country

Two new highly sensitive multiplexed amplicon sequencing panels, PvGTSeq and PvCRiSP, enable genomic surveillance of Plasmodium vivax malaria. The dataset, shared by Paulo C. Manrique-Valverde on figshare under a CC-BY-4.0 license, contains country-level data validated with samples from Colombia, Guyana, Honduras, Panama, and Venezuela. PvGTSeq requires selective whole-genome amplification and contains 249 amplicons, while PvCRiSP features four highly polymorphic amplicons and operates without sWGA.

Use Cases

• Estimating complexity of infection (COI) based on the PvCRiSP panel's four highly polymorphic amplicons.
• Identifying instances of clonal transmission based on the high sensitivity of both panels at low parasitemias.
• Assigning global geographic origin to imported malaria cases based on in-silico assessments using data from 16 countries.
• Characterizing recurrent malaria episodes based on the PvCRiSP panel's design.
• Analyzing population structure and antimalarial resistance based on PvGTSeq's 213 and 36 respective amplicons.

Strengths

• PvGTSeq contains 249 amplicons (36 for antimalarial resistance, 213 for population structure).
• Both panels achieve ≥75% amplicon recovery at parasitemias as low as five parasites/μL.
• PvGTSeq showed high sequencing accuracy with an error rate between 3.85e-4% and 2.87e-3%.
• Validated with samples from five countries and assessed in-silico using data from 16 countries worldwide.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is very small at 12.1 KB, indicating limited scope.

Provenance

Source

figshare, author Paulo C. Manrique-Valverde.

Collection Method

Data likely generated from multiplexed amplicon sequencing panels (PvGTSeq and PvCRiSP) validated with field samples.

Freshness

Last updated 2026-05-14 19:40:17; freshness should be verified.

Geography

Validated with samples from Colombia, Guyana, Honduras, Panama, and Venezuela; in-silico assessments used data from 16 countries worldwide.